One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations. 

All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.

Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.

The new warnings, first proposed to Pfizer and Moderna in April, are now officially required by the FDA. They provide additional information about the potential risks of myocarditis and/or pericarditis associated with these vaccines.

A new analysis provides further insight into factors affecting plaque stability and subsequent ischemic events

Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.

Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation.